Stock listing

Ptc Therapeutics, Inc.

Selected listing: P91 · BX · CHF · CH

Ptc Therapeutics, Inc. (BX Swiss: P91), Health Technology. Latest release Sep 21, 2026: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy.

P91:BXCHFCHUpdated October 2, 2026

Ticker: BX Swiss: P91
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: BX Swiss
Currency: CHF

Latest news from Ptc Therapeutics, Inc.

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 21, 2026

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

August 24, 2026

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

August 12, 2026

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

July 30, 2026

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

July 16, 2026

All Ptc Therapeutics, Inc. news →

Events

Replays

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call
Thu, Jul 30, 2026 · 04:30 PM ET
Watch
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call
Thu, May 07, 2026 · 04:30 PM ET
Watch
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call
Thu, Feb 19, 2026 · 04:30 PM ET
Watch

Research Ptc Therapeutics, Inc.

Ptc Therapeutics, Inc. company profile

View the public company page for Ptc Therapeutics, Inc. on 6ix.

Ptc Therapeutics, Inc. news

Read company news and market updates connected to Ptc Therapeutics, Inc..

Ptc Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Ptc Therapeutics, Inc..